Olesya Klychkova

Mrs. Olesya Klychkova

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
VKVictoria Alexandrovna Khotina
Victoria Alexandrovna Khotina
ALArthur Anatolievich Lee
Arthur Anatolievich Lee
DKDmitry Kashirskikh
Dmitry Kashirskikh
Olesya KlychkovaOlesya Klychkova
Olesya Klychkova
VNVitalia Sergeevna Novikova
Vitalia Sergeevna Novikova
TGTeymur Gasanov
Teymur Gasanov
Diabetic foot ulcers (DFU) are among the most severe complications of diabetes, resulting from a combination of metabolic dysregulation, vascular insufficiency, neuropathy, chronic inflammation, and impaired tissue repair, whereas diabetic foot infection (DFI) may develop within this compromised wound environment and frequently involves polymicrobial communities and biofilms. This review evaluates the mechanistic and translational basis for the use of antimicrobial peptides (AMP) in DFU and DFI, with emphasis on the diabetic wound microenvironment, polymicrobial ecology, endogenous AMP dysregulation, mechanisms of action, therapeutic development, and barriers to clinical translation. Hyperglycemia, ischemia, oxidative and proteolytic stress, and impaired innate immunity sustain inflammation, delay tissue repair, and promote microbial persistence. These conditions may also complicate antibiotic treatment through impaired tissue exposure and biofilm-associated tolerance. Depending on the peptide and experimental context, AMP may provide direct antimicrobial or antibiofilm activity and may also exert immunomodulatory or pro-reparative effects involving inflammatory signaling, angiogenesis, keratinocyte and fibroblast migration, and re-epithelialization. Approaches under investigation include engineered peptides, combination regimens, and local biomaterial-based platforms, including hydrogels, dressings, scaffolds, and nanoparticle-conjugated systems. Clinical translation remains constrained by proteolytic instability, potential host-tissue toxicity, limited selectivity, limited predictive value of preclinical models, heterogeneous clinical populations, nonstandardized endpoints, and manufacturing and regulatory requirements. Preclinical evidence supports further evaluation of approaches for local delivery of AMP, whereas clinical evidence in DFU and DFI remains limited and heterogeneous, with no AMP-based intervention yet demonstrating sufficiently consistent clinical benefit to support routine use.

Verified
Journal Article
Open access
PDF file
OVOlga Evgenevna Voronko
Olga Evgenevna Voronko
VNVitalia Sergeevna Novikova
Vitalia Sergeevna Novikova
Olesya KlychkovaOlesya Klychkova
Olesya Klychkova
MMMargarita Pavlovna Markina
Margarita Pavlovna Markina
ALArthur Anatolievich Lee
Arthur Anatolievich Lee
TGTeymur Gasanov
Teymur Gasanov
This review summarizes current knowledge on the role of human cathelicidin LL-37 in the regulation of apoptosis. LL-37 can modulate programmed cell death pathways, exerting either proapoptotic or antiapoptotic effects depending on various factors, such as cell type and peptide concentration. Data on LL-37 derivatives and their involvement in apoptosis are also discussed. Understanding the molecular mechanisms underlying LL-37 regulation of apoptosis is necessary to expand the therapeutic potential of this peptide in various pathological conditions, including cancer.

Verified
Journal Article
Open access
PDF file
ALArthur Anatolievich Lee
Arthur Anatolievich Lee
Maria Борисовна ChernyshevaMaria Борисовна Chernysheva
Maria Борисовна Chernysheva
DKDmitry Kashirskikh
Dmitry Kashirskikh
EREvgenii Ruchko
Evgenii Ruchko
Olesya KlychkovaOlesya Klychkova
Olesya Klychkova
AVAndrey Vasiliev
Andrey Vasiliev
Engineered bacteria are being explored as oral delivery systems for therapeutic peptides. This study examined Lactobacillus acidophilus expressing two GLP-1 peptide variants with N-terminal extensions, M-GLP-1 and M-6HIS-GLP-1, in male C57BL/6J mice with moderate streptozotocin (STZ)-induced hyperglycemia. Both purified peptides increased insulin concentrations in MIN6 conditioned medium after 24 h, but neither significantly attenuated the STZ-associated reduction in metabolic activity. Cage-level analysis showed lower average post-treatment glucose concentrations in mice receiving L. acidophilus expressing M-GLP-1 (Lacto-M-GLP-1) or M-6HIS-GLP-1 (Lacto-M-6HIS-GLP-1) than in STZ controls, but neither group differed significantly from mice receiving empty-vector L. acidophilus. The intraperitoneal glucose tolerance test showed numerically lower late-phase glucose concentrations and incremental area under the curve in both groups than in controls. Mice receiving Lacto-M-6HIS-GLP-1 showed greater body-weight change than those receiving Lacto-M-GLP-1 or empty-vector L. acidophilus. Pancreatic histology showed a lower pancreatic glucagon-positive signal area and a higher insulin-to-glucagon signal-area ratio than in STZ controls and Lacto-M-GLP-1. The findings demonstrate cellular responses to purified GLP-1 variants and metabolic changes associated with administering L. acidophilus expressing the peptides.